Status:
COMPLETED
Effect of Azimilide Dihydrochloride on Renal Function
Lead Sponsor:
Forest Laboratories
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study will assess the effect of multiple dosing of 125 mg azimilide on glomerular filtration rate (GFR) and total creatinine clearance (GFR + active secretion) in healthy subjects. Also, it will ...
Detailed Description
This is a double-blind, parallel-group, placebo-controlled, multiple-dose, single-site study in healthy male and female volunteers. Oral azimilide 125 mg or placebo will be administered every 12 hours...
Eligibility Criteria
Inclusion
- Male or hysterectomized or post-menopausal (last menstrual period \> 1 year) female
- Between 18 and 45 years of age, inclusive, at screening
- In good general health based on medical history, physical examination and laboratory evaluation
- Body mass index between 18 and 32 (kg/m2), inclusive
- Willing and able to fulfill the requirements of the protocol and provide written consent
Exclusion
- History of diabetes, cardiovascular, hepatic, renal, or gastrointestinal disease
- History of use of tobacco or nicotine-containing products within the past 3 months
- Alcohol or illicit drug abuse or a reported habitual alcohol intake greater than 1.5 oz. (ethanol equivalent) per day (e.g., 24 ozs. of beer, 10 ozs. of wine, or 3 ozs. of hard liquor) within the past 2 years.
- History of a clinically significant (in the opinion of the investigator) allergic reaction to any drug or multiple food/drug, contrast media agents, PAH, iodine or shell fish.
- Clinically significant abnormality upon physical examination that, in the investigator's opinion, would interfere with the conduct of the study
- Corrected QT-interval (QTc) \> 440 msec (QT interval corrected for heart rate using Bazett's formula).
- Clinically significant abnormality on screening 12-lead electrocardiogram (ECG); presence of discernable U wave that (in the investigator's opinion) would interfere with accurate measurement of QT at baseline and/or after treatment.
- Personal or family history of long QT syndrome
- Absolute neutrophil count \< 1500/mm3
- Potassium or magnesium value(s) outside the laboratory normal range
- Any other laboratory value(s) outside the laboratory normal range considered clinically significant by the investigator (serum chemistry, hematology, coagulation, or urinalysis.
- Serology positive for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) screen.
- If female, positive urine or serum pregnancy test
- Positive urine screen for drugs of abuse
- Reported use of any prescription drug or herbal preparations within 14 days prior to dosing or any non-prescription drug or vitamin within 7 days prior to dosing.
- Reported use of any known enzyme-inducer, enzyme-inhibitor, or other investigational drug within 30 days prior to dosing, or reported chronic exposure to enzyme-inducers such as paint solvents or pesticides within 30 days of dosing.
- Blood donation of approximately 400 mL or more within 4 weeks or plasma donation of 200 mL or more within 2 weeks prior to dosing.
- Acute illness within 2 weeks prior to dosing
- History or presence, upon clinical evaluation, of any illness that might impact the safety of test product administration or evaluability of drug effect based on the investigator's discretion.
- Has participated in another investigational drug study protocol within 30 days of admission.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00318838
Start Date
April 1 2006
End Date
May 1 2006
Last Update
February 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Parexel CPRU, Harbor Hospital Center
Baltimore, Maryland, United States, 21225